The Suitability of Tience® for Treating Acne Scars

Summary

This is an open-label, single-center, split-face, pseudo-randomized clinical trial designed to evaluate the efficacy and safety of a human-derived, cell-free adipose tissue derivative (Tience® ), for treating moderate to severe acne scars. Participants will receive three treatment sessions over a three-month period: on Day 0, Day 30, and Day 90. Treatment will be administered via injections to acne-scarred areas on one side of the face. The untreated side will be treated after the follow-up period. Outcomes will be evaluated over a twelve-month period using investigator clinical assessments, patient self-evaluation and VISIA skin analysis system to monitor changes in scar severity and overall skin quality.

Eligibility

Inclusion Criteria: healthy volunteers aged 18-40 years who have at least 3-year- old acne scars on their cheeks.

\-

Exclusion Criteria:

* pregnancy or nursing
* cancer or ongoing cancer treatment
* an active skin disease
* Fitzpatric scale 4-6 skin type
* a strong medication used for treating severe acne (e.g., Isotretinoin)
* active acne or Herpes
* antihistamine medication (if the medication can be paused for 7 days during study visits, participation is possible)
* use of biological medications
* tendency for excessive scar formation
* tendency for urticaria (hives)
* systemic medication affecting immunity
* autoimmune disease
* known disease affecting blood clotting (bleeding or thrombosis tendency) (e.g., von Willebrand disease)
* are allergic to the product being studied or any of its ingredients
* smoke

Conditions3

Browse More Trials